Dose escalation phase of the study completed up to the maximum planned dose of 20 mg/kg without dose-limiting toxicities (DLT) to date Preliminary patient pharmacodynamic (PD) data support continued clinical development Phase 1 study design featured at ASCO 2019...
The New Drug is a Category 1 innovative drug of the PRC developed by the Group. Representative Image Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular drug manufacturer in China’s prescription drug market, announced the third...
Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced that it has screened the first patient for its Phase 2a clinical trial evaluating...
The vast majority of clinical trial sponsors agree that unifying clinical data systems would accelerate study execution, improve study quality and lead to significant cost savings, yet few actually use this data to their benefit. In this free webinar, learn how to...
Proof of Concept Trial Reveal Significant Reduction in Cellulite with No Bruising, No Swelling and No Downtime after single 20-Minute non-invasive Procedure; Justifies proceeding with Pivotal Trial. Soliton, Inc., (SOLY) (“Soliton” or the...
Neuroblastoma is the most common extracranial solid cancer in children, and patients with high-risk disease are challenging to treat. In April, during the annual meeting of the American Society of Cell & Gene Therapy (ASGCT), researchers at Baylor College of...
Email
Text